CDC hails Merck's Rotateq for efficacy

Merck has yet another validation of its childhood vaccine Rotateq, designed to prevent rotavirus in infants and children: The CDC says the shot has led to a dramatic drop in hospitalization and ER visits since its debut two years ago, and even seems to be preventing illness in unvaccinated children. Report

Suggested Articles

It's taken years for Amarin's Vascepa to prove itself as a game-changing treatment for CV disease. An FDA committee may have just punched its pass.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

With a potential approval next year in the up-and-coming NASH field, Intercept is staffing up its sales team and starting talks with payers.